Orchestra BioMed Prices $75M Offering at $5.00, a Discount to the $5.62 Last Sale
OBIO sits 64% above its 52-week low of $3.46 on elevated volume (4.6× avg).
Summary
Orchestra BioMed priced a $75 million underwritten offering of 15 million shares at $5.00, below the $5.62 last sale, netting about $70.0 million to fund its BACKBEAT and Virtue trials through 2028.
Updates
· SEC 8-K — Orchestra BioMed closed the offering on November 9, 2026, raising $86.3 million gross after underwriters fully exercised their 2,250,000-share option.
- Offering Close — The underwriters' option for up to 2,250,000 additional shares, equal to 15% of shares sold, was exercised in full on November 6, 2026. The option was exercisable for 30 days from the Underwriting Agreement date.
- Pricing and Fees — The purchase price was $4.70 per share against a public offering price of $5.00 per share. The company reimburses underwriters' counsel fees and disbursements, including FINRA review fees, up to $200,000.
- Underwriting Agreement — The agreement dated November 5, 2026 was among Orchestra BioMed Holdings, Inc. and Piper Sandler & Co. and TD Securities (USA) LLC as representatives. Piper Sandler and TD Cowen are joint bookrunning managers, BTIG a bookrunner and H.C. Wainwright lead manager.
- Share Allocations — Firm shares total 15,000,000: Piper Sandler & Co. 6,600,000; TD Securities (USA) LLC 5,475,000; BTIG, LLC 2,250,000; H.C. Wainwright & Co., LLC 675,000.
- Use of Proceeds — Net proceeds, with existing cash and cash equivalents, fund the AVIM Therapy program, BACKBEAT global pivotal trial, Virtue SAB program, Virtue Trial, research and clinical development of other product candidates. The remainder is for working capital and general corporate purposes.
- Lock-Up Permitted Transfers — The lock-up permits gifts, trust, affiliate, estate and succession transfers, tax-withholding and option-exercise transfers, change-of-control transfers, pre-existing 10b5-1(c)(1)(i)(B) plans and merger or license consideration capped at 7.5% of shares outstanding immediately prior.
- Lock-Up Restrictions
- Lock-up bars hedging, short sales and registration demands without prior written consent of Piper Sandler & Co. and TD Securities (USA) LLC.
- Lock-up bars publicly disclosing the intention to make any offer, sale, pledge, disposition or filing, or to enter into any swap or other agreement transferring economic consequences of ownership.
- Lock-up transferees must agree in writing to be bound by the Lock-Up Agreement; the Company will issue stop-transfer instructions to the transfer agent for the Common Stock.
- Lock-Up Parties and Release
- Lock-up signatories: officers David P. Hochman, Darren R. Sherman, Andrew L. Taylor; non-employee directors Chris Cleary, Pamela A. Connealy, David Pacitti, Eric S. Fain, M.D., Jason Aryeh, John Mack.
- Lock-up covers officers David P. Hochman, Darren R. Sherman, Andrew L. Taylor and directors Chris Cleary, Pamela A. Connealy, David Pacitti, Eric S. Fain, M.D., Jason Aryeh, John Mack.
- Lock-up obligations release if the Offering is not completed by November 20, 2026.
- The undersigned is released from all obligations under the Lock-Up Agreement if the Company notifies the Underwriters that it does not intend to proceed with the Offering.
- Lock-up releases if the Underwriting Agreement does not become effective or terminates prior to the First Closing Date.
- Nasdaq and Validity — The company must file a Listing of Additional Shares Notification with Nasdaq and receive no objection. The securities will be validly issued, fully paid and nonassessable.
All 27 details
- Underwriting Agreement dated November 5, 2026 among Orchestra BioMed Holdings, Inc., Piper Sandler & Co. and TD Securities (USA) LLC as representatives of the underwriters.
- Firm shares: Piper Sandler & Co. 6,600,000; TD Securities (USA) LLC 5,475,000; BTIG, LLC 2,250,000; H.C. Wainwright & Co., LLC 675,000; total 15,000,000.
- Purchase price $4.70 per share; public offering price $5.00 per share.
- Company reimburses Underwriters' counsel fees and disbursements, including FINRA review fees, in an amount not to exceed $200,000.
- Company lock-up permits stock or securities issued as consideration for mergers, acquisitions, business combinations, strategic alliances, joint ventures, marketing or distribution arrangements, collaboration, co-promotion or IP license agreements, capped at 7.5% of shares outstanding immediately prior.
- Lock-up signatories: officers David P. Hochman, Darren R. Sherman, Andrew L. Taylor; non-employee directors Chris Cleary, Pamela A. Connealy, David Pacitti, Eric S. Fain, M.D., Jason Aryeh, John Mack.
- Underwriters' option to purchase up to 2,250,000 additional shares was exercised in full on November 6, 2026.
- Net proceeds to fund AVIM Therapy program and BACKBEAT global pivotal trial, Virtue SAB program and Virtue SAB in the Treatment of Coronary In-Stent Restenosis Trial, other product candidate research and clinical development, and remainder for working capital and general corporate purposes.
- Company must file a Listing of Additional Shares Notification with Nasdaq and receive no objection.
- Underwriter firm share allocations: Piper Sandler & Co. 6,600,000; TD Securities (USA) LLC 5,475,000; BTIG, LLC 2,250,000; H.C. Wainwright & Co., LLC 675,000.
- Lock-up covers officers David P. Hochman, Darren R. Sherman, Andrew L. Taylor and directors Chris Cleary, Pamela A. Connealy, David Pacitti, Eric S. Fain, M.D., Jason Aryeh, John Mack.
- Lock-up obligations release if the Offering is not completed by November 20, 2026.
- Lock-up permits gifts, trust transfers, affiliate transfers, estate transfers, and establishment of Rule 10b5-1(c)(1)(i)(B) plans with no sales during the Lock-Up Period.
- Lock-up bars hedging, short sales and registration demands without prior written consent of Piper Sandler & Co. and TD Securities (USA) LLC.
- Piper Sandler and TD Cowen are joint bookrunning managers; BTIG is a bookrunner; H.C. Wainwright & Co. is lead manager.
- Net proceeds, with existing cash and cash equivalents, to fund AVIM Therapy program, BACKBEAT global pivotal trial, Virtue SAB program, Virtue Trial, research and clinical development of other current or additional product candidates, remainder for working capital and other general corporate purposes.
- Company granted Underwriters an option, exercisable in whole or in part at any time for 30 days from the Underwriting Agreement date, to purchase up to 2,250,000 additional shares of Common Stock.
- The 30-day option covers up to an additional 15% of shares of common stock sold in the Offering, at the public offering price per share less underwriting discounts and commissions.
- Lock-up permits transfers pursuant to a change of control of the Company approved by the Board of Directors.
- Lock-up permits transfer of Undersigned's Securities pursuant to a Plan entered into by the undersigned prior to the date of the Underwriting Agreement and provided to the Representatives.
- Lock-up permits transfers to the Company to satisfy tax withholding obligations in connection with vesting or exercise of equity awards under the Company's equity incentive plans, or to cover the exercise price of outstanding options or warrants.
- Lock-up permits transfers by testate succession or intestate succession, and, if the undersigned is a trust, transfers to the beneficiary of such trust.
- Lock-up bars publicly disclosing the intention to make any offer, sale, pledge, disposition or filing, or to enter into any swap or other agreement transferring economic consequences of ownership.
- Lock-up transferees must agree in writing to be bound by the Lock-Up Agreement; the Company will issue stop-transfer instructions to the transfer agent for the Common Stock.
- The undersigned is released from all obligations under the Lock-Up Agreement if the Company notifies the Underwriters that it does not intend to proceed with the Offering.
- Lock-up releases if the Underwriting Agreement does not become effective or terminates prior to the First Closing Date.
- The Securities, when issued and sold against payment therefor, will be validly issued, fully paid and nonassessable.
Key Events · Financing and Capital Events · OBIO
-
15M Shares Priced at $5.00
Orchestra sold 15,000,000 shares at $5.00 for $75,000,000 gross, versus a $5.62 last reported sale price on November 5, 2026.
-
Net Proceeds About $70.0M
Underwriting discounts of $0.30 per share ($4,500,000) leave $70,500,000 before expenses, or roughly $70.0 million net; full exercise of the 2,250,000-share option would raise gross to $86,250,000 and net proceeds to about $80.5 million.
-
Dilution to New Buyers $3.68/Share
As adjusted net tangible book value rises to $1.32 per share from $0.49, an immediate $3.68 per share dilution to offering participants; shares outstanding go to 76,453,382 from 61,453,382.
-
Cash Runway Extended to 2028
Preliminary cash and marketable securities were about $102 million at September 30, 2026; with the deal, management expects funding through 2028, past the BACKBEAT data target in Q2 2027 and Virtue enrollment completion expected by end-2027.
Analysis · OBIO · Industrial Applications And Services
Orchestra priced 15 million shares at $5.00, below the $5.62 last reported sale on November 5, so buyers are getting a discount to the prevailing market and existing holders absorb roughly a quarter more shares. The $70.0 million net (about $80.5 million if the underwriters' option is fully exercised) is the difference between running two pivotal trials on schedule and having to raise again mid-study: management says the combined cash funds operations through 2028, covering the BACKBEAT data readout targeted for the second quarter of 2027 and the Virtue trial enrollment expected to finish by the end of 2027. The trade-off is real — new investors are diluted $3.68 per share in net tangible book value — but this is a company with $88K of quarterly revenue, so capital access is the whole story.
How filings like this one have moved
In the 30 days to Nov 9, 2026, 47.1% of the 1533 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, OBIO was trading at $5.68 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $341.4M. The 52-week trading range was $3.46 to $6.50. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.